Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerviron is a **medical device** formulated as vaginal ovules, indicated for the local treatment of acute and chronic vulvovaginitis of atrophic, aerobic, traumatic, and infectious causes, cervical erosions of traumatic or infectious origin, and bleeding due to these lesions. Its action is adjuvant in the restoration of vaginal pH and flora, especially after gynecological surgery. Cerviron’s mechanism relies on its active ingredients (bismuth subgallate, hexylresorcinol, hydrolyzed vegetable collagen, thyme extract, Hydrastis canadensis extract, calendula extract, turmeric extract) that promote re-epithelialization, healing of the cervical and vaginal mucosa, and reduction of symptoms including discharge, pruritus, bleeding, dysuria, and dyspareunia. Post-marketing and clinical studies demonstrate efficacy and tolerability, with a favorable safety profile. Cerviron does not act via classical pharmaceutical targets, but rather through physical-chemical and tissue-reparative properties grounded in its composite ingredients[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cerviron.